New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - posaconazole 100mg - modified release tablet - 100 mg - active: posaconazole 100mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry ii yellow 85f92209 - indicated for use in the treatment of the following invasive fungal infections in patients 18 years of age or older: - invasive aspergillosis in patients with disease that is refractory to, or are intolerant of, amphotericin b, itraconazole or voriconazole. - oesophageal candidiasis or candidemia in patients with disease that is refractory to, or who are intolerant of, amphotericin b, fluconazole, or itraconazole. - fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis, and mycetoma in patients with disease refractory to other therapy, or patients who are intolerant of other therapy. - coccidioidomycosis noxafil tablets are also indicated for use as: - prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients 13 years of age and older who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Kanada - Inggeris - Health Canada

merck canada inc - posaconazole - suspension - 200mg - posaconazole 200mg - azoles

Kanada - Inggeris - Health Canada

merck canada inc - posaconazole - tablet (delayed-release) - 100mg - posaconazole 100mg - azoles

Kanada - Inggeris - Health Canada

merck canada inc - posaconazole - solution - 300mg - posaconazole 300mg - azoles

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - posaconazole -

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

intervet international bv - orbifloxacin, mometasone furoate, posaconazole - otologicals - dogs - treatment of acute otitis externa and acute exacerbations of recurrent otitis externa, associated with bacteria susceptible to orbifloxacin and fungi susceptible to posaconazole, in particular malassezia pachydermatis.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

merck sharp & dohme corp. - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6), mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8), posaconazole (unii: 6tk1g07bhz) (posaconazole - unii:6tk1g07bhz) - indications: posatex® otic suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (malassezia pachydermatis) and bacteria (coagulase positive staphylococci, pseudomonas aeruginosa , and enterococcus faecalis ). contraindications : posatex® otic suspension is contraindicated in dogs with known or suspected hypersensitivity to quinolones, mometasone furoate monohydrate, or posaconazole. do not use in dogs with known tympanic perforation (see precautions ).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: propyl gallate; methacrylic acid - ethyl acrylate copolymer (1:1); xylitol; sodium stearylfumarate; triethyl citrate; microcrystalline cellulose; croscarmellose sodium; hyprolose; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - poscole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.,? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,poscole is also indicated for the prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.